Germany Drug Delivery Devices Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Germany Drug Delivery Devices Market Trends and Insights

High Prevalence and Incidence of Chronic and Infectious Diseases

Germany reports higher-than-EU-average prevalence for diabetes (8.4%), cardiovascular diseases (6.8%), and chronic respiratory diseases (11.4%).^{[1]Robert Koch Institute, “Health in Germany,” rki.de} This chronic-disease load drives steady demand for advanced injectors, insulin pens, smart pumps, and sustained-release implants that improve adherence and outcomes. Diabetes alone is projected to affect 10.9-14.2 million Germans by 2040, pushing continuous upgrades in automated insulin delivery ecosystems. Oncology demand follows a similar path: micro-/nano-robots under development at the German Cancer Research Center aim to raise tumour-site uptake while cutting systemic toxicity.^{[2]German Cancer Research Center, “Smart Technologies for Tumor Therapy,” dkfz.de} Together, disease trends and research breakthroughs keep the Germany drug delivery devices market on an innovation-driven trajectory.

Growing Trend of Home Healthcare and Aging Population

People aged ≥ 65 will rise from 21% of the population in 2023 to nearly 30% by 2050. Concurrently, those requiring long-term care could climb to 14 million by 2050. These shifts amplify the need for devices that non-professionals can use safely in domestic settings. On-body injectors such as Gerresheimer’s Gx SensAir® allow weekly subcutaneous dosing of monoclonal antibodies without clinical visits, cutting travel-related emissions and easing caregiver burdens. Consumer familiarity with telehealth platforms further accelerates uptake of connected inhalers, pens, and patches that integrate adherence dashboards, reinforcing market momentum in Germany drug delivery devices market.

Increasing Investment in Biosimilar and Biologics Product Innovation and Development

Biopharma sponsors are funnelling capital into mRNA, GLP-1, and cell-and-gene therapies that demand sophisticated containers and administration tools. SCHOTT Pharma boosted revenue from prefillable syringes by 54% to EUR 344 million in 2024 after expanding domestic capacity. Its TOPPAC freeze polymer syringe tolerates cryogenic storage for mRNA vaccines, while cartriQ cartridges target insulin and large-molecule drugs. Continuous spending by industry players underpins steady growth in the Germany drug delivery devices market.

Government Initiatives Supporting Fast Track Approval and Reimbursement

The Medical Research Act (October 2024) slashes red tape for clinical trials and first-in-human studies, compressing development timelines.^[3] Germany’s Digital-Health-Applications route reimburses lower-risk connected devices once positive care effect is proven, granting access to more than 90% of the insured population. Alignment with the EU Health Technology Assessment Regulation from 2025 streamlines post-launch benefit assessments, shortening the path from prototype to prescription and strengthening demand across the Germany drug delivery devices market.

Stringent Regulatory Requirements and Product Recalls

Germany enforces EU Medical Device Regulation (MDR) alongside its Medical Device Law Implementation Act. Combination products must satisfy dual drug-device evidence packages, and higher-risk classes require third-party conformity assessments.^{[3]Federal Institute for Drugs and Medical Devices, “Medical Research Act,” bfarm.de}Resulting cost spikes and recall liabilities weigh heaviest on SMEs, occasionally pausing launches and trimming the Germany drug delivery devices market growth curve.

The Federal Joint Committee assigns reference groups that set maximum reimbursable prices; devices lacking additional benefit evidence must sit at least 10% below comparators. While confidential prices are possible for select innovations, many premium connected or implantable systems still face tight margins, dampening aggressive commercial rollouts in the Germany drug delivery devices market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Device Type: Injectable Systems Maintain Leadership as Implants Accelerate

Injectable devices represented 43.02% of all revenues in 2025, cementing their role in the Germany drug delivery devices market size. Sustained demand arises from biologic therapies that dominate new drug approvals and from continuing preference among clinicians for parenteral accuracy. SCHOTT Pharma’s capacity surge in polymer and glass syringes underscores industry confidence. 

Implantable pumps, micro-chips, and bioresorbable depots post the quickest gains at an 9.96% CAGR. Patient-friendly inhalers preserve share amid a high national burden of chronic respiratory illness, while transdermal patches earn incremental adoption for hormone and pain management. Across categories, embedded connectivity features enhance dose logging and feedback loops, lifting adherence and data-driven care pathways within the Germany drug delivery devices market.

By Route of Administration: Injectable Dominance with Transdermal Upswing

Injectable delivery retained a 49.21% revenue stake in 2025, reflecting clinician trust in intravenous, subcutaneous, and intramuscular routes for vaccines and large-molecule drugs. This proportion anchors the Germany drug delivery devices market share and is bolstered by next-gen autoinjectors that lower activation force and support 2-5 mL volumes. 

Transdermal formats scale fastest at a 9.81% CAGR on the back of microneedle arrays and wirelessly powered acoustic patches that raise payload size limits. Oral mucosal films gain traction for rapid pain relief, while inhaled, ocular, and nasal modalities extend options for targeted local therapy, together enriching clinical toolkits available to practitioners in the Germany drug delivery devices market.

By Application: Diabetes Commands Revenues while Oncology Propels Future Growth

Diabetes accounted for 30.05% of the Germany drug delivery devices market size in 2025. Closed-loop AID systems that synchronise CGM and pump algorithms are now widely prescribed, with paediatric guidelines highlighting superior time-in-range during exercise scenarios. 

Oncology devices advance at a 9.73% CAGR as micro-robots, nanoparticle shuttles, and on-body injectors aim to chip away at hospital infusion visits. Cardiovascular, respiratory, and CNS segments maintain steady share, whereas infectious-disease applications spur interest in single-use dual-chamber syringes that simplify lyophilised vaccine reconstitution in the Germany drug delivery devices market.

By End-user: Hospitals Reign but Homecare Gains Ground

Hospitals generated 42.03% of 2025 turnover, reflecting concentration of complex oncology and critical-care infusions. Integrated pharmacy automation and staff familiarity with multi-channel pumps reinforce their centrality. 

Yet homecare settings are on a double-digit growth trajectory (10.62% CAGR) as statutory insurers reimburse nurse visits and connected devices for self-administration. Ambulatory surgical centres and specialist clinics fill the gap between inpatient and home use, widening distribution nodes for suppliers active in the Germany drug delivery devices market.

Geography Analysis

Germany’s advanced hospital density, export-oriented manufacturing, and universal insurance base combine to support a vibrant domestic ecosystem for drug delivery innovation. Nationwide reimbursement rules guarantee broad patient access while price corridors guide cost containment, creating predictable albeit competitive revenue pools. 

Urban Länder such as North-Rhine-Westphalia and Baden-Württemberg house clusters of device engineers, glass manufacturers, and pharma R&D hubs, accelerating prototype-to-pilot cycles. Eastern regions, historically underserved, are seeing targeted federal grants directed at digital-health rollouts and elder-care technology pilots, gradually balancing regional adoption. 

The demographic reality of a median age nearing 47 and an expanding cohort of multimorbid seniors ensures enduring demand for both high-acuity hospital devices and simplified self-care formats. This blend of sophisticated infrastructure and home-centred preferences cements Germany’s role as the reference market for European launches and attracts cross-border investment into the Germany drug delivery devices market.

Regulatory Landscape

Drug delivery devices and drug-device combination products in Germany are regulated under EU-level rules, led by the EU Medical Device Regulation (MDR) 2017/745 (as implemented and supplemented nationally through the Medizinprodukterecht-Durchfuehrungsgesetz, MPDG), with medicinal-product legislation (including Directive 2001/83/EC) determining the primary regulatory route based on the product's principal mode of action. Where a medicinal product integrates a device component, the device part must meet the MDR General Safety and Performance Requirements (GSPR) within the marketing authorization dossier, which adds documentation and testing depth for prefilled syringes, pens, on-body injectors, and other integrated systems.

Operationally, Germany uses BfArM processes for medical devices, including authorization of clinical investigations, and the German Medical Devices Information and Database System (DMIDS) remains the submission and data route in several areas until the European database EUDAMED becomes fully functional. The anticipated EUDAMED start point (noted as 28 May 2026 in BfArM-facing materials, followed by a transition period) is a near-term compliance anchor for manufacturers and importers managing registrations, vigilance reporting, and study administration alongside MDR conformity assessment requirements.

Value Chain Analysis

Germany's drug delivery devices value chain starts with upstream inputs such as specialty glass and metals, medical-grade polymers (including silicones and engineered resins), and precision tooling (micro-molds and components used in high-tolerance assemblies). Midstream work covers device design and engineering, component molding and machining, and regulated manufacturing under quality systems, followed by aseptic integration steps for drug-device combination products where device assembly, packaging, and coordination with fill-finish partners are required for ready-to-use formats used in injectables and cartridges.

Downstream, products move through warehousing and cold-chain or controlled logistics where needed, and distribution channels serving hospitals, clinics, ambulatory settings, and homecare. CDMO-style models are prominent for complex combination work, with companies such as Gerresheimer (device development and contract manufacturing) and Vetter (device assembly and packaging services) supporting pharma sponsors that need scalable, compliant production. On the system-enablement side, initiatives such as the COMBINE program (involving PEI, BfArM, and ethics committees) address administrative friction in combined studies across CTR, MDR, and IVDR, while industry feedback (for example, SPECTARIS survey findings highlighting widespread supply chain disruptions) points to persistent bottlenecks linked to regulatory burden, input availability, and cost pressures.

Market Opportunities and Future Outlook

The intersection of home-based therapy and biologics delivery offers a focused entry point, since Germany's chronic-disease load and insurer-backed care pathways reward devices that simplify self-administration while producing usable adherence evidence. Device makers are actively productizing this direction, including Gerresheimer's on-body delivery (Gx InPuls), autoinjector platform (Gx Inbeneo), and digital support add-on (Gx InMonit). These offerings align mechanical delivery with patient-support data flows that fit diabetes and oncology use cases already central to German demand.

Manufacturing and services capacity for combination products is a second opportunity cluster, spanning high-quality primary containers (syringes and cartridges), assembly, and regulated packaging, where German and Germany-linked suppliers differentiate on precision and compliance. Digitalization at both the company and system levels also creates practical pull for connected formats and information-enabled use, including the vfa-backed diGItal pilot that evaluates replacing printed package inserts with digital information (with implementation starting in Q3 2026). Alongside that, regulatory process modernization, including Germany's COMBINE initiative and the planned shift from DMIDS toward EUDAMED-based workflows, supports companies that invest early in data-ready compliance and post-market evidence generation for connected and combination delivery systems.